Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India

Citation: Suryavanshi N, Naik S, Waghmare S, Gupte N, Khan S, Mave V, Deluca A, Gupta A, Golub J, Bollinger RC, Shankar A. Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India. BMC Womens Health. 2018 Jan 15;18(1):19. doi: 10.1186/s12905-018-0515-2. PMID: 29334936. PMCID: PMC5769341.

Access full article:

https://www.ncbi.nlm.nih.gov/pubmed/29334936

Summary: 
Background: Gender-based violence (GBV) is a major global public health concern and is a risk factor for adverse health outcomes. Early identification of GBV is crucial for improved health outcomes. Interactions with health care providers may provide a unique opportunity for routine GBV screening, if a safe, confidential environment can be established.

Methods: Between November 2014 and February 2015, a cross-sectional, observational study was conducted where women were interviewed about their opinions concerning GBV screening in a tertiary health care setting in Pune, India. Trained counsellors interviewed 300 women at different out-patient and in-patient departments using a semi-structured questionnaire.

Results: Twenty-three percent of these women reported experiencing GBV in their life. However, 90% of women said they had never been asked about GBV in a health care setting. Seventy-two percent expressed willingness to be asked about GBV by their health care providers, with the preferred provider being nurses or counsellors. More than half (53%) women reported face-to-face interview as the most preferred method for screening. There were no major differences in these preferences by GBV history status.

Conclusions: Our study provides evidence for preferred GBV screening methods and optimal provider engagement as perceived by women attending a public hospital.

BMC Womens Health. 2018;18(1): e19

Categories

CRS
Topics

Clinical Trials

The Pharmacokinetics, Safety and Acceptability of New...

PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More